| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Sanchit Dhankhar, Samrat Chauhan, Dinesh Kumar Mehta, Nitika, Kamal Saini, Monika Saini, Rina Das, Sumeet Gupta, Vinod Gauta. Novel targets for potential therapeutic use in Diabetes mellitus. Diabetology & metabolic syndrome. vol 15. issue 1. 2023-02-14. PMID:36782201. |
in this journey, there are various treatments available in market to manage diabetes mellitus such as insulin, glp-1 agonist, biguanides, sulphonyl ureas, glinides, thiazolidinediones targeting the receptors which are discovered decade before. |
2023-02-14 |
2023-08-14 |
Not clear |
| Katsunori Nonogaki, Takao Kaj. Ingestion of whey protein and β-conglycinin exerts opposite effects on intestinal FGF15 and serotonin secretion in mice. Frontiers in endocrinology. vol 14. 2023-02-13. PMID:36777350. |
moreover, ingestion of whey protein isolate significantly decreased the expression of tgr5, glucagon-like peptide 1 (glp-1), and tryptophan hydroxylase1 (tph1) in the small intestine, leading to decreases in plasma 5-ht and insulin levels. |
2023-02-13 |
2023-08-14 |
mouse |
| Katsunori Nonogaki, Takao Kaj. Ingestion of whey protein and β-conglycinin exerts opposite effects on intestinal FGF15 and serotonin secretion in mice. Frontiers in endocrinology. vol 14. 2023-02-13. PMID:36777350. |
moreover, ingestion of β-conglycinin significantly increased the expression of intestinal tgr5, glp-1, and tph1, leading to increases in plasma 5-ht and insulin levels. |
2023-02-13 |
2023-08-14 |
mouse |
| Andrea I Dâ Aquino, Caitlin L Maikawa, Leslee T Nguyen, Katie Lu, Ian A Hall, Alexander N Prossnitz, Enmian Chang, Sam W Baker, Catherine M Kasse, Carolyn K Jons, Jerry Yan, Lars Hovgaard, Dorte B Steensgaard, Hanne B Andersen, Lotte Simonsen, Eric A Appe. Sustained Delivery of GLP-1 Receptor Agonists from Injectable Biomimetic Hydrogels Improves Treatment of Diabetes. bioRxiv : the preprint server for biology. 2023-02-13. PMID:36778223. |
glucagon-like peptide-1 (glp-1) is an incretin hormone and neurotransmitter secreted from intestinal l-cells in response to nutrients to stimulate insulin and block glucagon secretion in a glucose-dependent manner. |
2023-02-13 |
2023-08-14 |
rat |
| Yajun Wu, Yao Wang, Dongmin Li. Identification of Genipin as a Potential Treatment for Type 2 Diabetes. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36768454. |
it has been well recognized that glucagon-like peptide-1 (glp-1), which is an incretin hormone secreted from intestinal l-cells, plays a vital role in regulating glycemic homeostasis via potentiating glucose-stimulated insulin secretion and promoting β-cell function. |
2023-02-11 |
2023-08-14 |
Not clear |
| Gabriela Tavares, Daniela Rosendo-Silva, Flávia Simões, Hans Eickhoff, Daniela Marques, Joana F Sacramento, Adriana M Capucho, Raquel Seiça, Sílvia V Conde, Paulo Matafom. Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue. International journal of molecular sciences. vol 24. issue 3. 2023-02-11. PMID:36768789. |
given that dopamine is secreted by the gut and regulates insulin secretion in the pancreas, we aimed to determine its regulation by nutritional cues and its role in regulating glucagon-like peptide 1 (glp-1) action in wat. |
2023-02-11 |
2023-08-14 |
human |
| Akshaya Bansal, Jing Zhang, Qi Lu, Qingsong Mei, Yong Zhan. Tether-free optogenetic control of insulin secretion using an upconversion nanoparticle-doped hydrogel platform. Biomaterials science. 2023-02-01. PMID:36723390. |
glucagon-like peptide-1 (glp-1), as a molecular therapeutic, induces glucose-dependent stimulation of insulin secretion, which has drawn significant attention in treating type ii diabetes. |
2023-02-01 |
2023-08-14 |
rat |
| Akshaya Bansal, Jing Zhang, Qi Lu, Qingsong Mei, Yong Zhan. Tether-free optogenetic control of insulin secretion using an upconversion nanoparticle-doped hydrogel platform. Biomaterials science. 2023-02-01. PMID:36723390. |
moreover, the glp-1 produced in this platform was sufficient to increase insulin secretion in rat insulinoma cells, providing a powerful and controllable therapeutic tool for diabetes. |
2023-02-01 |
2023-08-14 |
rat |
| Eleonora Grespan, Andrea Mar. Does glucose lowering restore GIP effects on insulin secretion? Nutrition, metabolism, and cardiovascular diseases : NMCD. 2023-01-29. PMID:36710118. |
renewed interest for this phenomenon has been expressed in the context of the new dual gip-glp-1 (glucagon-like peptide-1) receptor agonists, which have shown greater efficacy of this drug class compared with single glp-1 receptor agonists, including on insulin secretion. |
2023-01-29 |
2023-08-14 |
Not clear |
| Lukasz Buldak, Grzegorz Machnik, Estera Skudrzyk, Aleksandra Boldys, Mateusz Maliglowka, Michal Kosowski, Marcin Basiak, Rafal Jakub Buldak, Boguslaw Okopie. Exenatide prevents statin-related LDL receptor increase and improves insulin secretion in pancreatic beta cells (1.1E7) in a protein kinase A-dependent manner. Journal of applied biomedicine. vol 20. issue 4. 2023-01-28. PMID:36708718. |
the concomitant use of glp-1 receptor agonist seemed to successfully revert insulin expression. |
2023-01-28 |
2023-08-14 |
Not clear |
| Michael A Nauck, Mirna Abd El Aziz, Daniel R Quas. Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin - An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide. Diabetes, obesity & metabolism. 2023-01-26. PMID:36700380. |
meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin - an update including recently developed glp-1 receptor agonists and the gip/glp-1 receptor co-agonist tirzepatide. |
2023-01-26 |
2023-08-14 |
Not clear |
| Michael A Nauck, Mirna Abd El Aziz, Daniel R Quas. Meta-Analysis of Head-to-Head Clinical trials Comparing Incretin-Based Glucose-Lowering Medications and Basal Insulin - An Update Including Recently Developed GLP-1 Receptor Agonists and the GIP/GLP-1 Receptor Co-Agonist Tirzepatide. Diabetes, obesity & metabolism. 2023-01-26. PMID:36700380. |
to assess comparative efficacy, safety and tolerability of injectable incretin-based glucose-lowering medications (ibglm) versus basal insulin treatment in patients with type 2 diabetes research design and methods: we performed an updated meta-analysis of randomized clinical trials of head-to-head comparisons of ibglm (short- and long-acting glp-1 receptor agonists [glp-1 ras] and gip/glp-1 receptor co-agonist tirzepatide) vs. basal insulin using pubmed database search (april 2022). |
2023-01-26 |
2023-08-14 |
Not clear |
| Correction to: "GLP-1 Receptor Agonists and SGLT-2 Inhibitors as Adjuncts to Insulin in Type 1 Diabetes: Benefits and Concerns". The Journal of clinical endocrinology and metabolism. 2023-01-19. PMID:36656760. |
correction to: "glp-1 receptor agonists and sglt-2 inhibitors as adjuncts to insulin in type 1 diabetes: benefits and concerns". |
2023-01-19 |
2023-08-14 |
Not clear |
| Reema Abu Khalaf, Ebtisam Alwarafi, Dima Sabba. Piperazine sulfonamides as DPP-IV inhibitors: Synthesis, induced-fit docking and Acta pharmaceutica (Zagreb, Croatia). vol 71. issue 4. 2023-01-18. PMID:36651550. |
dipeptidyl peptidase-iv (dpp-iv) inhibitors minimize glucagon and blood glucose levels by increasing the incretin levels, glucagon-like peptide (glp-1) and glucose-dependent insulinotropic poly-peptide (gip), leading to insulin secretion from pancreatic beta cells. |
2023-01-18 |
2023-08-14 |
Not clear |
| André J Schee. Dual GIP/GLP-1 receptor agonists: new advances for treating type-2 diabetes. Annales d'endocrinologie. 2023-01-13. PMID:36639119. |
because of the complementarity of action of the two incretins, tirzepatide showed better dose-dependent (5, 10 and 15 mg) efficacy (greater reduction in hba1c and body weight) than placebo, basal insulin or two glp-1 analogues (dulaglutide and semaglutide) in the surpass program. |
2023-01-13 |
2023-08-14 |
Not clear |
| Shammi Akter, Shajia Afrin, Jaeyoon Kim, Joohyun Kang, Md Abdur Razzak, Per-Olof Berggren, Inhwan Hwan. Production of active Exendin-4 in Frontiers in plant science. vol 13. 2023-01-09. PMID:36618620. |
production of active exendin-4 in glp-1 (glucagon-like peptide-1) is a peptide that stimulates insulin secretion from the β-cell for glycemic control of the plasma blood glucose level. |
2023-01-09 |
2023-08-14 |
Not clear |
| Giovanni Targher, Alessandro Mantovani, Christopher D Byrn. Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease. The lancet. Gastroenterology & hepatology. vol 8. issue 2. 2023-01-09. PMID:36620987. |
glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic polypeptide (gip) are incretins that stimulate insulin secretion from pancreatic β cells in response to food ingestion. |
2023-01-09 |
2023-08-14 |
Not clear |
| Nanna Thurmann Jørgensen, Trine Møller Erichsen, Morten Buus Jørgensen, Thomas Idorn, Bo Feldt-Rasmussen, Jens J Holst, Ulla Feldt-Rasmussen, Marianne Klos. Glucose metabolism, gut-brain hormones, and acromegaly treatment: an explorative single centre descriptive analysis. Pituitary. 2023-01-07. PMID:36609655. |
the objective of the study was to describe the differential effect of various treatment regimens on the secretion of glucose, insulin, glucagon, glucagon-like peptide-1 (glp-1), and glucose-dependent insulinotropic polypeptide (gip) in patients with acromegaly. |
2023-01-07 |
2023-08-14 |
Not clear |
| Alexandros Leonidas Liarakos, Anastasios Tentolouris, Alexandros Kokkinos, Ioanna Eleftheriadou, Nikolaos Tentolouri. Impact of Glucagon-like peptide 1 receptor agonists on peripheral arterial disease in people with diabetes mellitus: A narrative review. Journal of diabetes and its complications. vol 37. issue 2. 2023-01-07. PMID:36610322. |
glucagon-like peptide 1 (glp-1) receptor agonists (glp-1ras) are among the latest class of antidiabetic medications that stimulate insulin synthesis and secretion and have been used for the management of type 2 dm. |
2023-01-07 |
2023-08-14 |
Not clear |
| Jean-François Yale, Aude Roborel de Climens, Naresh Aggarwal, Terry Dex, Hertzel C Gerstein, Stewart Harris, Irene Hramiak, John Stewart, Lawrence A Leite. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers. Diabetes therapy : research, treatment and education of diabetes and related disorders. 2022-12-27. PMID:36574199. |
for people with type 2 diabetes mellitus who do not achieve glycated hemoglobin a1c targets after treatment with basal insulin therapies, additional therapy with a glucagon-like peptide-1 receptor agonist (glp-1 ra) may be required. |
2022-12-27 |
2023-08-14 |
Not clear |